Literature DB >> 16238145

Chemotherapy for metastatic disease: current status.

J Graham1.   

Abstract

Chemotherapy now has an established role in the treatment of hormone-refractory metastatic prostate cancer. This review summarises the results of the latest trials and discusses ongoing studies investigating the role of chemotherapy earlier in the disease.

Entities:  

Mesh：

Year:  2005        PMID： 16238145     DOI： 10.1016/j.clon.2005.07.010

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  2 in total

1.  Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer.

Authors:  Rainer Kuefer; Felicitas Genze; Waltraud Zugmaier; Richard E Hautmann; Ludwig Rinnab; Juergen E Gschwend; Marina Angelmeier; Aidee Estrada; Berthold Buechele
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

2.  RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

Authors:  Kilian M Gust; Matthias D Hofer; Sven R Perner; Robert Kim; Arul M Chinnaiyan; Sooryanarayana Varambally; Peter Moller; Ludwig Rinnab; Mark A Rubin; Jochen Greiner; Michael Schmitt; Rainer Kuefer; Mark Ringhoffer
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.